Bauer D, Keller J, Alt M, Schubert A, Aufderhorst UW, Palapys V, Kasper M, Heilingloh C, Dittmer U, Laffer B, Eis-Huebinger AM, Verjans GM, Heiligenhaus A, Roggendorf M, Krawczyk A (2017)
Publication Type: Journal article
Publication year: 2017
Book Volume: 512
Pages Range: 194-200
DOI: 10.1016/j.virol.2017.09.021
The increasing incidence of aciclovir- (ACV) resistant strains in patients with ocular herpes simplex virus (HSV) infections is a major health problem in industrialized countries. In the present study, the humanized monoclonal antibody (mAb) hu2c targeting the HSV-1/2 glycoprotein B was examined for its efficacy towards ACV-resistant infections of the eye in the mouse model of acute retinal necrosis (ARN). BALB/c mice were infected by microinjection of an ACV-resistant clinical isolate into the anterior eye chamber to induce ARN and systemically treated with mAb hu2c at 24h prior (pre-exposure prophylaxis) or at 24, 40, and 56h after infection (post-exposure immunotherapy). Mock treated controls and ACV-treated mice showed pronounced retinal damage. Mice treated with mAb hu2c were almost completely protected from developing ARN. In conclusion, mAb hu2c may become a reliable therapeutic option for drug/ACV-resistant ocular HSV infections in humans in order to prevent blindness.
APA:
Bauer, D., Keller, J., Alt, M., Schubert, A., Aufderhorst, U.W., Palapys, V.,... Krawczyk, A. (2017). Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections. Virology, 512, 194-200. https://doi.org/10.1016/j.virol.2017.09.021
MLA:
Bauer, Dirk, et al. "Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections." Virology 512 (2017): 194-200.
BibTeX: Download